Rheumatic Diseases: Diagnosis and Management

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1572

Special Issue Editor


E-Mail Website
Guest Editor
Department of Internal Medicine, Division of Rheumatology, Dell Medical School, The University of Texas, 1601 Trinity St., Austin, TX 78712, USA
Interests: cell biology; gene expression; molecular medicine; molecular neurobiology; rheumatism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Rheumatic disease treatment paradigms are becoming increasingly complex. Recognition of new autoimmune and autoinflammatory conditions, side effects related to immunotherapy, and complications arising from post-pandemic-related symptoms coupled with the burgeoning landscape of biologic therapies together with various immunomodulators targeting alternative inflammatory pathways has enabled for a plethora of new approaches targeting many longstanding conditions. Our increased knowledge base gives afflicted individuals more options; however, it also increases the complexity of treatment decisions for practitioners. The goal of this Special Issue is to focus on selected areas in rheumatology and provide evidence-based approaches to diagnosis and/or management for these conditions.

Prof. Dr. Kevin V. Hackshaw
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rheumatic diseases
  • biomarker
  • diagnosis
  • diagnostic techniques
  • rheumatic heart disease
  • rheumatoid arthritis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

10 pages, 1626 KiB  
Review
Comprehensive Exploration of Antinuclear Antibodies (ANAs): Unveiling Clinical Significance, Associations with Cancer, and the Nuances of Differential Diagnosis in Positive ANA Patients
by Krasimir Kraev, Bozhidar Hristov, Petar Uchikov, Maria Kraeva, Yordanka Basheva-Kraeva, Siyana Valova, Maria Koleva-Ivanova, Stanislava Popova-Belova, Milena Sandeva, Dzhevdet Chakarov and Mariela Geneva-Popova
Diagnostics 2024, 14(3), 320; https://doi.org/10.3390/diagnostics14030320 - 01 Feb 2024
Viewed by 1335
Abstract
This comprehensive review delves into the complex realm of antinuclear antibodies (ANAs), expanding beyond their traditional involvement in autoimmune rheumatic disorders. By digging into historical changes, diagnostic complexity, and clinical significance, the debate reveals the shifting relationships between ANAs, particularly with cancer. Specialized [...] Read more.
This comprehensive review delves into the complex realm of antinuclear antibodies (ANAs), expanding beyond their traditional involvement in autoimmune rheumatic disorders. By digging into historical changes, diagnostic complexity, and clinical significance, the debate reveals the shifting relationships between ANAs, particularly with cancer. Specialized studies provide practical insights on ANA testing processes, standardization, and upcoming challenges. Examining prevalence trends in the United States provides a time dimension to ANA dynamics, linking autoimmune and oncological considerations. The debate delves into the complexity of lupus erythematosus, emphasizing ANAs’ diverse presentations and their potential as flexible diagnostic and prognostic indicators. The complex relationship between ANAs and cancer is highlighted, demonstrating their potential as early markers or indicators of malignancies. Looking ahead, this synthesis anticipates advances in personalized medicine and collaborative research, putting ANAs at the forefront of advanced diagnostics and treatments for autoimmune disorders and cancer. This synthesis envisions a future for ANA research in which these antibodies play a critical role in promoting personalized treatment, enhancing diagnostics, and fostering collaborative initiatives that cross traditional boundaries. As ANAs grow more prominent at the junction of autoimmune illnesses and cancer, this synthesis lays the path for further research and novel advances in understanding, diagnosing, and treating complicated medical conditions. Full article
(This article belongs to the Special Issue Rheumatic Diseases: Diagnosis and Management)
Show Figures

Figure 1

Back to TopTop